United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 94.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 800 shares of the biotechnology company’s stock after selling 13,826 shares during the quarter. UniSuper Management Pty Ltd’s holdings in United Therapeutics were worth $282,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Signaturefd LLC raised its position in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after buying an additional 30 shares during the last quarter. Parallel Advisors LLC boosted its holdings in United Therapeutics by 2.8% in the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 30 shares during the last quarter. Great Lakes Advisors LLC grew its position in United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after purchasing an additional 31 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after buying an additional 33 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after buying an additional 39 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $308.27 on Tuesday. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The business has a fifty day moving average price of $339.04 and a 200 day moving average price of $355.62. The company has a market cap of $13.85 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period last year, the firm posted $4.36 earnings per share. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on UTHR. UBS Group raised their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $940,373.07. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,500 shares of company stock worth $26,134,500 in the last ninety days. Insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.